Johan Harmenberg
Associate Director
Medical Science
Oxypharma
Sweden
Biography
Chief Excecutive Officer, Axelar AB, Associate Professor in Virology at the Karolinska Institute. Previous employments include: Clinical Research Director, Medical Advisor and Medical Director at Roche, Astra and Pharmacia & Upjohn and Vice President, Development, Medivir AB. Involvement with OxyPharma: Dr. Harmenberg was the first person to work with B-220 from an anti-viral perspective and has been involved in the activities around B-220 since the late 1980's. Currently, Dr. Harmenberg is involved in issues concerning clinical trials and regulatory work.
Research Interest
His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.
